DUBLIN--(BUSINESS WIRE)--The "Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.
The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, experiencing a CAGR of 9.4% during the forecast period.
Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.
Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.
Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.
Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
Chapter 4 Global Psoriasis Drugs Market Overview
Chapter 5 Global Psoriasis Drugs Market: Pipeline Intelligence
Chapter 6 Company Profiles
Chapter 7 Market Outlook
- AbbVie Inc.
- Amgen, Inc.
- Johnson & Johnson
- Novartis AG
- Eli Lilly and Company
- Celgene Corporation
For more information about this report visit https://www.researchandmarkets.com/research/2j63jf/global_psoriasis?w=4